Endpoints News Webinar: Why Australia is the World’s Leading Early Phase Destination – plus up to 50% cost savings

Why Australia is the World’s Leading Early Phase Destination – Rapid Start-up, No IND Required, and a Government-Backed Refund on Almost Half of all Trial Costs Increasingly Sponsors are wanting to be actively involved in the core clinical partner selection because they matter to the success of their clinical research. The biotech industry knows that the right biolab and Phase 1 Unit partners are just as vitally important as CRO selection. In this webinar, you will hear from Agilex Biolabs and Phase 1 contract research organization CMAX about how they work together, and with local and global CROs, to deliver world-class clinical research outcomes. FDA-inspected Agilex Biolabs is the leading bioanalytical laboratory in Asia Pacific with the most advanced platforms for sensitive technologies, including Gyrolab, to develop state-of-the art assays. Agilex Biolabs has supported hundreds of studies conducted across Australia, Asia Pacific and Europe with the most accurate and quality-controlled bioanalytical services. Our scientists have a breadth of knowledge and experience in ligand binding assays, antidrug-antibody assays and neutralising antibody assays with in-depth expertise in troubleshooting immunogenicity assays which can often be challenging to develop, to meet the high drug and target tolerance. CMAX Clinical Research is a leading Phase 1 clinical research organization, literally 10 minutes away from Agilex Biolabs, in South Australia. CMAX, established in 1993, was the first dedicated early phase research facility in Australia and is one of Australia’s largest and most experienced clinical trial centres. The expert team is committed to supporting innovative medical research in partnership with national and international Sponsors. CMAX is now the Asia Pacific’s ‘go-to’ early phase unit. This webinar will cover how this long-standing relationship between Agilex Biolabs and CMAX delivers significant advantages to biotechs wanting a streamlined and collaborative approach to their early phase studies. CMAX also has a Site Management Organisation offering, working with General Practitioners to conduct clinical trials. This offering will be soon branded as Fusion Clinical Research.